High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy

Westermann, Dirk H; Studer, Urs E (2009). High-risk clinical stage I nonseminomatous germ cell tumors: the case for chemotherapy. World journal of urology, 27(4), pp. 455-61. Berlin: Springer-Verlag 10.1007/s00345-009-0456-3

[img]
Preview
Text
345_2009_Article_456.pdf - Published Version
Available under License Publisher holds Copyright.

Download (280kB) | Preview

Testis cancer is the most frequent solid malignancy in young men. The majority of patients present with clinical stage I disease and about 50% of them are nonseminomatous germ cell tumors. In this initial stage of disease there is a subgroup of patients at high risk with a likelihood of more than 50% for relapse. Treatment options for these patients include: retroperitoneal lymph node dissection (RPLND), albeit 6-10% of patients will relapse outside the field of RPLND, active surveillance with even higher relapse rates and adjuvant chemotherapy. As most of these patients have the chance to become long-term survivors, avoidance of long-term side effects is of utmost importance. This review provides information on the potential of chemotherapy to achieve a higher chance of cure for patients with high-risk clinical stage I disease than its therapeutic alternatives and addresses toxicity and dose dependency.

Item Type:

Journal Article (Further Contribution)

Division/Institute:

04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Urology

UniBE Contributor:

Studer, Urs

ISSN:

0724-4983

Publisher:

Springer-Verlag

Language:

English

Submitter:

Factscience Import

Date Deposited:

04 Oct 2013 15:13

Last Modified:

05 Dec 2022 14:22

Publisher DOI:

10.1007/s00345-009-0456-3

PubMed ID:

19636566

Web of Science ID:

000268985700007

BORIS DOI:

10.7892/boris.32203

URI:

https://boris.unibe.ch/id/eprint/32203 (FactScience: 197184)

Actions (login required)

Edit item Edit item
Provide Feedback